

c) Remarks

The claims are 21 - 34, with claims 21, 22, 33 and 34 being independent claims. Claims 21 and 22 have been amended to add a period, thereby correcting a syntax error not related to patentability. Claims 21 and 22 have been amended also to delete compounds (CT-6) and (CT-9) from the claims.

The triphenylamine compounds claimed in the present invention are only (CT-1), (CT-3), (CT-5) and (CT-8). United States Patents 5,430,526 to Ohkubo ("Ohkubo"), 4,859,556 to Sasaki ("Sasaki") and 5,098,809 to Kikuchi ("Kikuchi") fail to disclose these compounds (CT-1), (CT-3), (CT-5) and (CT-8). Thus, the Examiner's art rejection is moot since the cited references fail to disclose the triphenylamine compounds claimed in the instant invention.

New claims 33 and 34 claim the phosphine compounds and palladium compounds that have been used in the Examples in the instant specification.

Applicants believe that they have now addressed the Examiner's specific concerns and request that the subject application be passed to issue.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212)218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Attorney for Applicants

Registration No.

24947

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

NY_MAIN 362127v1